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bone loss in DM [1–5]. Similarly, DM is a risk factor for
fractures [5–7], although there is no difference in the
risk of fractures between type I DM and type II DM [1].
Patients with type I DM demonstrate a decrease in
osteoblast function caused by insulin deficiency [8],
whereas it is difficult to clarify the mechanism for the
reduction in bone mineral density (BMD) in type II
DM. Hyperglycemia causes increased fractional excre-
tion of both Ca2 and uric acid in type II DM patients
[9]. Similarly, hyperglycemia influences the responses of
osteoblasts to parathyroid hormone (PTH) and 1.25-
dihydroxyvitamin D (1,25 (OH)2D3) [10,11]. However,
many conflicting results have also been presented, in
which hyperinsulinemia prevents bone loss in type II
DM patients [12]. Recently, bone histomorphometry
from the DM transiliac has demonstrated that the meta-
bolic effects of poor glycemic control lead to low bone
turnover, which retards age-related bone loss. A reduc-
tion in bone turnover may increase bone fragility, inde-
pendent of bone density [13].
There is evidence that the levels of undercarboxy-
lated osteocalcin (UcOC) increase in elderly people
with bone fractures. A defect in vitamin K metabolism
plays a role in hip fractures [14] and in BMD in elderly
women [15]. Epidemiologically, a diet insufficient in
vitamin K was also associated with higher morbidity,
due to femoral neck fractures [16]. These studies en-
dorse the view that vitamin K can prevent bone frac-
tures in the elderly and is involved in bone metabolism.
The role of vitamin K in type II DM is not well known
in terms of its effects on bone metabolism. In osteo-
porotics, vitamin K enhances the accumulation of
osteocalcin in the extracellular matrix of human osteo-
blasts in vitro [17]. Whether or not there is a defect in
vitamin K metabolism that causes osteoblast dysfunc-
tion in type II DM is still unclear. In order to elucidate
the role of vitamin K in elderly diabetic patients with
osteoporosis, we measured the levels of vitamin K,
caliciotropic hormones, BMD, and bone biochemical
Abstract We conducted a cross-sectional examination of the
role of serum vitamin K levels as they relate to bone metabo-
lism in elderly women with type II diabetes mellitus (DM).
Eighty-five elderly women with type II DM were enrolled.
Three fractions of vitamin K, phylloquinone (PK), mena-
quinone 4 (menatetrenone; MK 4), and menaquinone 7 (MK
7), along with undercarboxylated osteocalcin (UcOC), intact
osteocalcin (IOC), urinary deoxypyridinoline (udpd), urinary
type I collagen N-telopeptide (NTx), and intact parathyroid
hormone (IPTH) were measured. Bone mineral density was
measured in the lumbar spine (LSBMD) by dual-energy X-ray
absorptiometry (DXA), and T scores or Z scores were calcu-
lated. The patients were divided into two groups by T score,
under 2.5 (osteoporotic group) and over 2.5 (non-
osteoporotic group). UcOC levels in osteoporotics patients
were significantly higher than those in the non-osteoporotic
group (3.09  3.94 vs 1.82  1.76 ng/ml, P  0.02). The corre-
lation between Z score and logarithmic UcOC/IOC levels in
type II DM showed a negative trend (P  0.07) and a
significantly and negatively association with logarithmic NTx
(r  0.38; P  0.001). In osteoporotic DM, the UcOC/IOC
ratio was significantly correlated with the Z score (r  0.61;
P  0.05). Furthermore, logarithmic UcOC/IOC showed a
negative correlation with logarithmic MK 7 (r  0.50; P 
0.001). In conclusion, the reduction in LSBMD in elderly
women with type II DM may be associated, in part, with a
defect in γ-glutamylcarboxylation by vitamin K.
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Introduction
The mechanisms for the development of osteopenia or
osteoporosis in type II diabetes mellitus (DM) remain
controversial. There is conflicting evidence concerning
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markers in elderly women with type II DM. We ana-
lyzed the significance of vitamin K metabolism from the
standpoint of bone reduction in elderly women with
type II diabetes.
Subjects and methods
Study design and subjects
Eighty-five subjects without vertebral deformities or
fractures, as ascertained by lumbar X-ray, were selected
to join this study. All subjects agreed to participate in
the study by giving their informed consent under
the guidelines of the Ethics Committee of the Tokyo
Metropolitan Geriatric Medical Center. Patients taking
prescribed bisphosphonates, alfacalcidol, menatrenone,
ipriflavone, anabolic steroids, calcitonin, estrogen, insu-
lin, thiazide, or statins were excluded by questionnaire,
as were those frequently consumed “natto” (a type of
fermented soybeans) or those who had consumed natto
within a week priot to the study, and those who had
symptoms of secondary osteoporosis caused by such
conditions as hyperthyroidism, hyperparathyroidism,
Cushing’s syndrome, gastrectomy, or immobilization.
The DM subjects were divided into two groups, by T
scores (osteoporotics; T  2.5) and non-osteoporotics
(T  2.5). Parameters including glycohemoglobin, du-
ration of DM, and years since menopause were com-
pared between the two groups.
Bone biochemical markers and calciotropic
hormone assays
Undercarboxylated osteocalcin (UcOC,), intact osteo-
calcin (IOC), and bone-specific alkaline phophatase
(BAP) were chosen as markers of bone formation,
while urinary deoxypyridinoline (udpd), and urinary
type I collagen N-telopeptide (NTx) were used as mark-
ers of bone resorption. Blood and urine samples were
collected in the morning following an overnight fast.
Aliquots of blood and urine were frozen at 20∞C until
analyzed. Intact PTH (IPTH) and IOC were measured
by immunoradiometric assays (IRMA). UcOC was
measured with a specific enzyme-linked immunosor-
bent assay (ELISA) [18]. We also measured udpd and
NTx by ELISA. Intraassay and interassay variances in
the measurements were 6.9% and 3.5% respectively, for
IPTH, 4.8% and 5.4% for IOC, 6.4% and 3.1% for NTx,
7.5% and 10.1% for udpd, and 7.2% and 7.9% for
UcOC.
Vitamin K assay
Serum concentrations of three fractions of vitamin K,
phylloquinone (PK), menaquinone 4 (menatetrenone;
MK 4) and menaquinone 7 (MK 7), were determined
by high-performance liquid chromatography separa-
tion with fluorescence detection [19]. Intraassay and
interassay variances in the measurements were 3.8%
and 3.0%, respectively, for PK, 3.8% and 4.4% for MK
4, and 5.5% and 2.7% for MK 7.
Bone mineral density (BMD) measurement
BMD was measured at the level of the second to fourth
lumbar vertebrae (LSBMD) by dual-energy X-ray
absorptiometry (DXA; Lunar IQ, Madison, WI, USA).
T scores and Z scores for LSBMD were calculated as
percentages of the values in young controls and in age-
matched controls, respectively, based on the Lunar
database of healthy Japanese women. Spillover in the
calibration of the Lunar IQ apparatus was 7.8%.
Statistical analysis
All values are expressed as means SD unless other-
wise indicated. Groups were compared using unpaired
t-tests, with P  0.05 considered statistically significant.
The correlations between independent and dependent
factors were analyzed by Pearson’s coefficient, with
SPSS software, after converting to logarithmic (log)
values.
Results
MK 4 levels in DM was detectable in only 12 subjects in
this study. Therefore, we did not include MK 4 in fur-
ther analyses. Baseling age, body mass index (BMI),
BMD, and years since menopause are shown in Table 1.
Only UcOC levels were higher in osteoporotics than in
non-osteoporotics (3.09  3.94 vs 1.82  1.76 ng/ml; P 
0.02), as shown in Table 2. No differences were ob-
served between osteoporotics and non-osteoporotics in
IPTH or bone biochemical markers (Table 2). There
was a negative trend between Z score and log (UcOC/
IOC) (P  0.07), and a significant association with NTx
in elderly DM patients (P  0.01; Fig. 1a,b). The corre-
lation between logarithmic UcOC/IOC and logarithmic
MK 7 in elderly diabetics is shown in Fig. 2. Log (UcOC/
IOC) was negatively and significantly correlated with
log MK 7 (r  0.50; P  0.001). In osteoporotic DM
patients, the ratio UcOC to IOC was significantly corre-
lated with the Z score (r  0.61; P  0.05), as shown
in Table 3 and in Fig. 3, but this correlation was not seen
in non-osteoporotic DM patients.
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Discussion
Among the baseline characteristics analyzed, there was
a significant difference in UcOC values between non-
osteoporotic DM and osteoporotic DM. However, nei-
ther PK nor MK 7 concentrations differed between
non-osteoporotic and osteoporotic groups. MK 7 con-
centrations in osteoporotic DM women were slightly
higher than those in non-osteoporotic group, although
MK-7 levels were significantly correlated with UcOC/
IOC in DM, as shown in Fig. 2. This paradox suggests
that sufficient levels of vitamin K are present in DM, but
that it does not promote the γ-glutamyl carboxylation of
undercarboxylated osteocalcin (UcOC). Presumably,
the γ-carboxylation of UcOC by vitamin K may be im-
paired in elderly patients with osteoporotic DM. It has
been reported that anticoagulant therapy, which inhib-
its γ-glutamylcarboxylase activity, reduces bone mineral
content at the lumbar spine and distal radius [20]. Hy-
Table 1. Comparison of baseline characteristics between elderly women with non-
osteoporotic (non-op) DM and osteoporotic (op) DM
Non-op (n  70) Op (n  15) P value
Age (years) 69.8  3.8 71.7  5.5 0.15
BMI 23.1  2.7 21.3  2.9 0.47
YSM 18.7  3.5 21.2  5.2 0.27
HbA1c (%) 7.30  1.31 7.35  1.14 0.96
Duration of DM (years) 13.1  6.8 10.3  8.9 0.65
L2-4 BMD 1.03  0.13 0.732  0.06 0.03
T score 0.73  1.14 3.23  0.55 0.02
Z score 1.16  1.25 0.8  0.73 0.06
There were significant differences in L2-4 BMD values and T scores between the non-osteoporotic
and osteoporotic DM patients
DM, diabetes mellitus; BMI, body mass index; YSM, years since menopause; Hb, hemoglobin;
BMD, bone mineral density
Table 2. Comparisons of vitamin K, IPTH, and bone bio-
chemical markers between non-osteoporotic DM and
osteoporotic DM patients
Non-op Op P
(n  70) (n  15) value
PK (ng/ml) 1.1  0.9 0.9  0.5 0.22
MK7 (ng/ml) 8.1  9.8 11.83  13.5 0.27
IPTH (pg/ml) 31.1  9.1 32.34  12.7 0.38
UcOC (ng/ml) 1.82  1.76 3.09  3.94 0.02
IOC (ng/ml) 9.67  3.37 9.85  2.72 0.49
udpd (nmol/mmolCr) 6.3  1.7 6.6  1.7 0.81
NTx (nmolBCE/mmolCr) 32.1  15.8 37.2  15.8 0.77
UcOC levels in osteoporotic DM (n  15) were significantly higher
than those in non-osteoporotic DM (n  70)
PK, phylloquinone; MK7 menaquinone 7; IPTH, intact parathyroid
hormone; UcOC, urder-carboxylated osteocalcia; IOC, intact
































Fig. 1 a Correlation between Z
score and log undercarboxylated
osteocalcin (UcOC) in elderly
diabetes mellitus (DM) patients.
There is a negative trend between
the Z score and log (UcOC/intact
osteocalcin [IOC]) in ederly pa-
tients with DM b Correlation be-
tween Z score and log urinary type
I collagen N-telopeptide (NTx) in
DM. The Z score was significantly
correlated with log NTx
Table 3. Correlation coefficients between Z score and IPTH
and bone biochemical markers in non-osteoporotic and oste-
oporotic DM patients
Non-osteoporotics Osteoporotics
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mately 7.3%, indicating that glucose was moderately
controlled. PTH secretion in elderly diabetics was also
within the normal range in out assay. The induction of
γ-glutamylcarboxylase as well as vitamin K epoxidase is
regulated by 1,25(OH)2D3 in vivo in rat kidney [25].
Similarly γ-glutamylcarboxylase in human osteoblasts
is induced by pretreatment of 1,25(OH)2D3 [26].
Therefore, it may be necessary to measure serum
1,25(OH)2D3 concentrations in elderly diabetics with
increased UcOC levels.
So far, NTx, among bone resorption markers, is the
most sensitive predictor of bone loss in the lumbar
spine. Markers of bone resorption can be used clinically
to predict future BMD in postmenopausal women [27].
In our study, Z scores showed a significant associa-
tion with NTx in DM patients. Similarly, UcOC/IOC
showed a negative association with the Z score, which
indicates that the increase of UcOC may be associated
with an increase in bone resorption and a decrease of
LSBMD in DM. It has been reported that vitamin K
concentrations are not correlated with BMD, but may
have an association with bone quality, as determined by
ultrasonic transmitted velocity [28]. Thus, vitamin K
seems to be more involved in bone quality than in bone
quantity, as the carboxylation of osteocalcin as related
to bone quality has been proposed as a possible mecha-
nism for the prevention of bone fractures by vitamin K
[29]. Bone volume and trabecular structure in rats sub-
jected to longterm tail suspendsion are maintained by
vitamin K2 [30]. Diabetics, as well as astronauts, may
rely on vitamin K metabolism for bone formation and
bone resorption.
In summary, the levels of UcOC were higher in os-
teoporotic than in non-osteoporotic elderly patients
with type II DM. MK 7 levels in osteoporotics were
somewhat higher than those in non-osteoporotics, de-
spite a significant negative association of MK 7 with
UcOC concentrations. These results suggest that im-

















Fig. 2. Correlation between log UcOC/IOC and log
menaquinone (MK) 7 in elderly DM women. Log (UcOC/































Fig. 3. Correlations between z score
and UcOc/IOC in non-osteoporotic
and osteoporotic DM patients. The Z
score was significantly correlated
with UcOC/IOC in osteoporotic DM
patients. NS, not significant
perglycemia, as well as anticoaglants, may decrease γ-
glutamylcarboxylase activity in diabetic osteoporotics.
Thus, it is necessary to examine whether or not
hyperglycemia results in a direct decrease in the
activity of γ-glutamylcarboxylase. A decrease in γ-
glutamylcarboxylase activity and an increase in
undercarboxylated gla protein may induce the reduc-
tion of bone mineral content [21]. Our results are com-
patible with these results.
The onset of complications in DM, such as retinopa-
thy and nephropathy, is dependent on the control of
glucose and the duration of the disease. Bone loss is
also associated with the duration of DM and insulin
deficiency [22]. However, there were no significant
correlations between the non-osteoporotic DM and os-
teoporotic DM patients in our study. Additionally, nei-
ther age nor BMI differed between the osteoporotics
and non-osteoporotics. Hyperglycemia hampers the re-
sponse of osteoblasts to 1,25(OH)2D3 in vitro [23] and
inhibits PTH secretion [23,24]. However, there was no
significant difference between the non-osteoporotic
DM and osteoporotic DM groups in glycohemoglobin, a
parameter that reflects glucose control in diabetics.
Glycohemoglobin levels in both groups were approxi-
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the reduction in bone mineral content in elderly dia-
betic women.
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